Stockreport

Celldex Presents Data Demonstrating Barzolvolimab Improves Chronic Spontaneous Urticaria Independent of Baseline Immunoglobulin E levels in Phase 2 Study at EADV Congress 2025

Celldex Therapeutics, Inc.  (CLDX) 
Last celldex therapeutics, inc. earnings: 11/12 08:01 am Check Earnings Report
US:NASDAQ Investor Relations: ir.celldex.com
PDF HAMPTON, N.J., Sept. 17, 2025 (GLOBE NEWSWIRE) -- Celldex (NASDAQ:CLDX) announced today new data demonstrating rapid and strong efficacy regardless of baseline immunog [Read more]